'Real' Evidence Generating Real Pre- And Post-Market Benefits

The rise of high-quality real-world data (RWD) and real-world evidence (RWE) is transforming drug development and how regulatory agencies make decisions. This shift is evident in the FDA's 2023 guidance for using RWE in regulatory submissions. As a valuable complement to traditional clinical trials, RWE has the potential to revolutionize the pharmaceutical industry, improve patient care, and ensure equitable access to new medications.

In this Q&A, Kourtney Davis, Vice President of Global Epidemiology at Johnson & Johnson Innovative Medicine, joins Wyatt Gotbetter, Value and Access Editor at Global Forum, to discuss the current and future applications of RWD/E in drug discovery, clinical research, regulatory review and approval, and its role in promoting health equity and patient and provider access.

Access the full Q&A to learn more.